人工智能在眼睛运动中的分析对阿尔茨海默病的早期诊断
Shadi Farabi Maleki1, Milad Yousefi2, Navid Sobhi1
1Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Current Alzheimer research
|June 6, 2024
概括
人工智能 (AI) 与眼动分析相结合,为早期发现阿尔茨海默病提供了一种新的非侵入性方法. 机器学习模型显示高精度,有望改善临床评估和个性化治疗.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病 (AD) 是一个日益严重的全球健康问题,特别影响老年人.
- 目前对AD的诊断方法可能具有侵入性或缺乏足够的早期检测能力.
- 人工智能 (AI) 算法显示出提高医疗保健机构诊断准确性的潜力.
研究的目的:
- 审查关于整合人工智能技术与眼动分析以检测阿尔茨海默病的文献.
- 评估人工智能驱动的眼动分析作为AD的非侵入性诊断工具的潜力.
- 突出这一方法对早期诊断和个性化治疗的承诺.
主要方法:
- 我们对2024年3月1日之前发表的英语文章进行了系统的搜索.
- 在数据库中搜索了研究AI,眼动和阿尔茨海默病的交叉点的研究.
- 专注于人工智能技术,如机器学习和深度学习 (例如卷积神经网络).
主要成果:
- 通过人工智能增强的眼动分析,可以潜在地检测出阿尔茨海默病的认知变化.
- 机器学习模型在使用眼动数据对阿尔茨海默病进行分类时表现出高准确度.
- 深度学习方法,如卷积神经网络,显示出希望,但需要更多的数据进行精确的分类.
结论:
- 人工智能驱动的眼动分析为早期和准确的阿尔茨海默病诊断提供了一种新的非侵入性策略.
- 这种方法可以显著提高临床评估,并促进量身定制的治疗计划.
- 将人工智能系统与眼动分析相结合,为克服早期AD检测当前挑战提供了一个有希望的途径.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.0K
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
